Intucell Proves Superiority with Unique Commercialization of 'OHPAS Linker' "Verification of Versatility for Various Drugs"

[Financial News] Intucell, which possesses core technology in the field of Antibody-Drug Conjugates (ADC), is attracting industry attention by proving the superiority of its 'Cleavable Linker', the only one successfully commercialized worldwide through its self-developed 'OHPAS Linker' platform technology.
According to related industries on the 29th, the OHPAS Linker is an innovative technology with a cleavable structure that selectively releases drugs only within cancer cells, while existing very stably in the bloodstream. Subsequently, it is a structure that induces an anticancer effect by cleaving the linker and drug only in specific environments within cancer cells.
The key point is that it has a structure that can be applied to drugs with oxygen groups, which are abundant in nature. This shows a distinct differentiation and versatility, as the currently only commercialized competing technology can only be applied to drugs with nitrogen groups.
This technology has various strengths compared to competing technologies, including chemical and biological stability, high versatility applicable to oxygen-based drugs, fast drug dissociation rate, compatibility with various antibody-linker combinations, and synthesis efficiency in terms of pharmaceutical manufacturing and quality control (CMC), supported by a multitude of experimental data.
In addition, Intucell has also developed the 'PMT (Payload Modification Technology)' platform, a selectivity enhancement technology. PMT improves the non-selective cell uptake issue of ADC by introducing hydrophilic polar groups to the drug and enhances the Therapeutic Index (TI).
An industry official stated, “Intucell's OHPAS Linker technology is an innovative technology that maximizes the therapeutic effect of ADC while simultaneously satisfying stability and application range,” adding, “There is a great possibility of expanding technological cooperation with global pharmaceutical companies as a commercialized platform for oxygen-based cleavable linkers.”
dschoi@fnnews.com Choi Doo-sun Reporter